Highlight Capital

Highlight Capital is a Shanghai-based growth investor that has positioned itself at the intersection of foundational AI work and the clinical research ecosystem in China. The firm is comfortable engaging with companies whose product roadmaps require multi-year scientific validation alongside aggressive commercial execution, and it tends to favor teams that can credibly span both domains.

The healthcare focus runs through biotech, AI/ML in healthcare, and health IT and healthcare software. Within that, Highlight has been associated with companies building foundation models for biological data, AI-enabled clinical research networks, and software that connects pharmaceutical sponsors with clinical sites and patient populations. The thesis treats AI not as a feature but as a structural change in how drug development and clinical research are organized, and the firm prefers companies whose data assets and workflow integration give them durable defensibility against larger incumbents.

Check sizes run from $5M to $25M, with the fund active across Series A, Series B, and growth rounds. That positioning makes Highlight a natural participant in rounds where companies are scaling commercial operations and need capital to support multi-site deployments, regulatory work, and international expansion. Founders should expect substantive engagement on commercial strategy and capital structure, as well as candor about the realities of operating healthcare AI companies inside the Chinese regulatory environment and in cross-border configurations.

The team brings investing, operating, and pharmaceutical industry backgrounds, with relationships across Chinese hospital systems, contract research organizations, and pharmaceutical companies. Those relationships are a meaningful part of what Highlight offers portfolio companies, particularly those whose go-to-market depends on integration with clinical research infrastructure or on partnerships with pharma sponsors. The firm is comfortable being patient with companies whose underlying science requires extended validation and whose commercial ramp follows a non-linear path.

For founders, working with Highlight means an investor that is engaged on strategy and governance, that expects rigorous reporting, and that is willing to support portfolio companies through extended development cycles. Post-investment activity tends to focus on commercial introductions, follow-on syndication, and helping companies navigate the increasingly complex environment for healthcare and AI investing in China and adjacent markets. The fund is a less natural fit for early-stage companies still finding product-market fit, given its growth-stage check sizes, and it is a less obvious choice for companies whose primary market is the US or Europe. It is a strong fit for scientifically credible teams whose business depends on integration with Chinese clinical research and pharmaceutical infrastructure and who want an investor with the relationships and capital to support that path. The firm’s tone with founders tends to be direct and substantive rather than promotional.